| Human immunodeficiency virus I infection
Odefsey vs Sunlenca
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Odefsey vs Sunlenca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSunlenca has a higher rate of injection site reactions vs Odefsey based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sunlenca but not Odefsey, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Odefsey
Sunlenca
At A Glance
Oral
Once daily
NRTI + NNRTI combination
SC injection
Every 6 months
HIV-1 capsid inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (emtricitabine 200 mg, rilpivirine 25 mg, tenofovir alafenamide 25 mg) orally once daily with a meal
Human immunodeficiency virus I infection (Initiation Option 1) Day 1: 927 mg SC injection (2 x 1.5 mL) plus 600 mg oral (2 x 300 mg tablets); Day 2: 600 mg oral (2 x 300 mg tablets); then 927 mg SC every 6 months (26 weeks) for maintenance.
Human immunodeficiency virus I infection (Initiation Option 2) Days 1 and 2: 600 mg oral (2 x 300 mg tablets); Day 8: 300 mg oral (1 x 300 mg tablet); Day 15: 927 mg SC injection (2 x 1.5 mL); then 927 mg SC every 6 months (26 weeks) for maintenance.
Contraindications
- Coadministration with carbamazepine
- Coadministration with oxcarbazepine
- Coadministration with phenobarbital
- Coadministration with phenytoin
- Coadministration with rifampin
- Coadministration with rifapentine
- Coadministration with dexamethasone (more than a single dose)
- Coadministration with St. John's wort
- Coadministration with proton pump inhibitors
- Concomitant use of strong CYP3A inducers
Adverse Reactions
Most common (>=2%) Headache, sleep disturbances
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight increased, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Most common (>=3%) Injection site reactions, nausea
Serious Grade 3 injection site reactions (erythema, pain, swelling)
Postmarketing Injection site necrosis
Pharmacology
Odefsey is a fixed-dose combination of emtricitabine (an NRTI that inhibits HIV-1 reverse transcriptase by chain termination), rilpivirine (an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase), and tenofovir alafenamide (a prodrug that is converted to tenofovir, an NRTI inhibiting HIV-1 reverse transcriptase by chain termination).
Lenacapavir is a multistage, selective HIV-1 capsid inhibitor that directly binds to capsid protein (p24) subunits in hexamers, inhibiting multiple essential steps of the viral lifecycle including capsid-mediated nuclear uptake of proviral DNA, virus assembly and release, and capsid core formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Odefsey
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
Sunlenca
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Odefsey
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Sunlenca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Odefsey
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Sunlenca
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Gilead Advancing Access Co-Pay Program: SunlencaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OdefseyView full Odefsey profile
SunlencaView full Sunlenca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.